Writing the next chapter in GI health
Vedanta is advancing first-in-class Live Biotherapeutic Products (LBP) to treat serious gastrointestinal diseases using defined consortia of bacteria.
Writing the
next chapter
in GI health
Vedanta is advancing first-in-class
Live Biotherapeutic Products (LBP) to treat
serious gastrointestinal diseases
using defined consortia of bacteria.
Commitment to Patients
Gut dysbiosis is a known driver of gastrointestinal diseases. Our drugs can stimulate a range of protective responses which hold potential for the treatment of these diseases.
C. difficile Infection
Clostridium difficile (C. diff), a type of bacteria, is one of the most common causes of health care-associated infections and has also emerged as a cause of community-associated infections.
Defined Bacterial Consortia
We are developing oral therapies using defined bacterial consortia to treat a range of debilitating diseases with an initial focus on prevention of recurrent Clostridium difficile infection.
Clinical Trials
Vedanta is conducting clinical trials in recurrent Clostridium difficile infection to evaluate the efficacy and safety of potential drug candidates.
Advanced clinical-stage pipeline
explore our pipeline
Working at Vedanta
At Vedanta Biosciences, we share a passion for groundbreaking scientific work to improve the lives of patients.